Many pharmaceutical companies listed on National Chengda Biotech Innovation Board release Q3 financial reports

Sichuan Province issued the implementation rules for the management of traditional Chinese medicine granules; Takeda announced the acquisition of the γδT cell therapy platform; Yibai Pharmaceutical plans to acquire 70% of the shares of Deyang Cancer Hospital for 336 million yuan.
.
.
Part1 Policy Brief Sichuan Province issued the rules for the management of traditional Chinese medicine granules on the 27th, Sichuan The Provincial Food and Drug Administration issued a notice on the issuance of the "Detailed Regulations for the Management of Traditional Chinese Medicine Formula Granules in Sichuan Province", which made specific explanations on the management of various types of Chinese medicine prescription granules, such as variety registration, production, circulation and use supervision, and stipulated that the notice will be in November It will be implemented on the 1st
.
(Sichuan Provincial Food and Drug Administration) Hunan Province launches review of intermediate and junior professional titles for pharmacy.
Recently, Hunan Provincial Food and Drug Administration issued the "Notice on Doing a Good Job in the First Evaluation of Provincial Pharmaceutical Professionals (Non-clinical Units) for the First and Junior Professional Titles
.
" According to the "Notice", in order to accelerate the reform of the pharmacy professional title system, in accordance with the spirit of the relevant documents, Hunan Province has started the evaluation of the junior and junior professional titles of pharmacy starting this year
.
(Hunan Provincial Drug Administration) Part2 Industry Economics Observation Chengda Biotechnology Innovation Board closed down 27.
27% on the first day of listing on the 28th, Chengda Biotechnology officially listed on the Science and Technology Innovation Board, the issue price is 110 yuan / share, the opening price is 89.
99 yuan /Share, opened 18.
19% lower, and the stock price continued to fall after the opening; as of the day's close, Chengda Biotechnology closed at 80 yuan/share, a decrease of 27.
27%, with a total market value of 33.
316 billion
.
(Sina Pharmaceutical News) Takeda announced the acquisition of the γδT cell therapy platform on the 27th, Takeda announced that it exercised its option to acquire GammaDelta Therapeutics, and will acquire GammaDelta's γδT cell therapy platform, including the same species of γδT cell subgroup Vδ1+ cells based on blood and tissue sources.
Allogeneic cell immunotherapy project
.
This acquisition expands Takeda’s combined pipeline of immuno-oncology and innate immune cell therapy to develop potential therapies for solid tumors and hematological malignancies
.
(Wuxi AppTec) Yibai Pharmaceutical plans to acquire a 70% stake in Deyang Cancer Hospital for 336 million yuan.
On the 27th, Yibai Pharmaceutical announced that it intends to acquire a 70% stake in Deyang Cancer Hospital Co.
, Ltd.
for 336 million yuan; after the completion of the acquisition , Deyang Cancer Hospital will become the company’s holding subsidiary and be included in the company’s consolidated statements
.
(Corporate Announcement) Ganli Pharmaceutical: Net profit in the third quarter was 499 million yuan, a year-on-year increase of 32%.
On the 27th, Ganli Pharmaceuticals announced that it achieved operating income of 1.
028 billion yuan in the third quarter, a year-on-year increase of 4.
40%; net profit attributable to shareholders of listed companies 499 million yuan, a year-on-year increase of 31.
72%
.
Basic earnings per share are 0.
89 yuan
.
(Company announcement) Tonghua Dongbao: Net profit in the third quarter was 394 million yuan, an increase of 83.
72% year-on-year.
On the 27th, Tonghua Dongbao announced that it achieved operating income of 793 million yuan in the third quarter, a year-on-year increase of 11.
52%; net profit attributable to the parent was 3.
94 100 million yuan, an increase of 83.
72% year-on-year; non-net profit attributable to parent deductions was 246 million yuan, an increase of 17.
17% year-on-year; basic earnings per share were 0.
19 yuan
.
(Corporate Announcement) Nanwei Medical: Net profit of 105 million yuan in the third quarter increased by 11% year-on-year.
On the 27th, Nanwei Medical announced that it achieved operating income of 514 million yuan in the third quarter, a year-on-year increase of 42.
63%; attributable to shareholders of listed companies Net profit was 105 million yuan, a year-on-year increase of 11.
28%
.
Basic earnings per share are 0.
7893 yuan
.
(Corporate Announcement) International Medicine: A net loss of 225 million yuan in the third quarter.
On the 27th, International Medicine announced that it achieved operating income of 742 million yuan in the third quarter, a year-on-year increase of 71.
71%; net profit attributable to the parent was a loss of 225 million yuan
.
(Corporate Announcement) China Cell: The third quarter net loss was 224 million yuan.
On the 27th, China Cell issued an announcement stating that the third quarter achieved operating income of 10.
045.
8 million yuan, a year-on-year increase of 12144.
77%; net profit attributable to shareholders of listed companies-224 million yuan Yuan; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is -227 million yuan; basic earnings per share is -0.
51 yuan
.
(Company announcement) Wantai Bio: Net profit in the third quarter was 467 million yuan, a year-on-year increase of 109% 100 million yuan, an increase of 109.
39% year-on-year; non-net profit attributable to parent deductions was 462 million yuan, an increase of 111.
59% year-on-year; basic earnings per share were 0.
76 yuan
.
(Corporate Announcement) Zhifei Biological: The net profit in the third quarter was 2.
913 billion yuan, a year-on-year increase of 199.
06%
.
On the 28th, Zhifei Biological issued an announcement stating that the net profit in the first three quarters was 8.
404 billion yuan, a year-on-year increase of 239.
05% .
Among them, the net profit in the third quarter was 2.
913 billion yuan, a year-on-year increase of 199.
06%
.
(Corporate Announcement) Part3 Drug News of Hengrui's PD-L1 monoclonal antibody in the treatment of extensive-stage small cell lung cancer Phase III successful The main endpoints of the randomized, double-blind, placebo-controlled, multi-center phase III clinical study of lung cancer reached the pre-specified superiority standard
.
The results of the study showed that adbelimumab combined with chemotherapy compared with placebo combined with chemotherapy achieved a significant and clinically significant prolonged overall survival
.
(Sina Pharmaceutical News) Beihai Kangcheng CAN008 injection for the treatment of GBM in Phase II clinical treatment of GBM completed the first patient in China on the 26th, Beihai Kangcheng announced that its CAN008 injection for the treatment of glioblastoma phase II clinical study in mainland China Complete the first patient's administration
.
(PR Newswire) BTK targeted protein degradation therapy NX-2127 received the first clinical proof-of-concept on the 28th, Nurix Therapeutics announced that its targeted degradation therapy of Bruton's tyrosine kinase NX-2127 is in phase 1 clinical trials Not only can it degrade more than 90% of BTK protein, but it also showed preliminary clinical activity in a patient with chronic lymphocytic leukemia.
This is the first time that a targeted protein degradation strategy has obtained clinical proof of concept in patients with hematological malignancies
.
(Immediate drug news) Phase 2 clinical trial of innovative TCR therapy combined with blockbuster immune checkpoint inhibitors is about to start.
Recently, TCR2 Therapeutics announced that it has reached a clinical trial cooperation agreement with Bristol-Myers Squibb
.
TCR2 will conduct a phase 2 clinical trial to evaluate the T-cell receptor cell therapy gavo-cel combined with PD-1 inhibitor Opdivo and CTLA-4 inhibitor Yervoy for the treatment of unresectable, metastatic or relapsed mesothelin expression Efficacy for patients with sexual cancer, including non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma
.
(Wuxi Ming AppTec) Ji'ankang TT-00420, a drug for cholangiocarcinoma, obtained FDA fast-track qualification.
On the 27th, Ji'ankang announced that the FDA has granted the company's core product TT-00420 fast-track qualification for the treatment of cholangiocarcinoma without standard treatment options.
Patient
.
(Wuxi AppTec) Novartis Kymriah's new indication enters review treatment in the United States and Europe r/r FL Recently, Novartis announced that the FDA and EMA have respectively accepted CD19 CAR-T cell therapy Kymriah's supplementary biological product license application and Class II change: use For the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 therapies
.
(Biology Valley) Novo Nordisk's basal insulin GLP-1RA injection Novo? was approved for marketing in China.
Recently, NMPA approved Novo Nordisk's GLP-1RA injection Novo? It is suitable for adults with type 2 diabetes with poor blood sugar control
.
It can be combined with other oral hypoglycemic drugs on the basis of diet and exercise to improve blood sugar control .
(NMPA) Yangzijiang Pharmaceutical's Moxifloxacin Hydrochloride Eye Drops was approved to be marketed on the 28th.
The official website of NMPA showed that Yangzijiang Pharmaceutical's Moxifloxacin Hydrochloride Eye Drops, which imitated Category 4 products, were approved for marketing.
The approval number is the National Medicine Standard.
The word H20213835
.
Moxifloxacin is a fourth-generation quinolone drug developed by Novartis.
On the basis of retaining the broad-spectrum antibacterial activity, antibacterial efficacy and safety advantages of quinolone, it significantly enhances anti-Gram-positive levofloxacin eye drops compared with the most widely used clinically used levofloxacin eye drops.
The activity of bacteria, anaerobic bacteria and resistant bacteria
.
(NMPA) The listing application of Hengrui Pharmaceuticals SHR3680 tablets is planned to be reviewed for the treatment of prostate cancer on the 28th.
The official website of the CDE shows that the listing application of Hengrui SHR3680 tablets is planned to be included in the priority review and started to be publicized for the treatment of metastatic hormone sensitivity with high tumor burden.
Patients with prostate cancer
.
(CDE) The listing application of Roche entrectinib capsules is planned to be included in the priority review.
On the 28th, the information on the CDE website showed that the listing application of Roche entrectinib capsules is planned to be included in the priority review, and the indication is "NTRK fusion-positive locally advanced or metastatic solid tumors
.
" (CDE) Qilu Pharmaceutical applied for the world’s first generic olaparib on the 28th, the CDE official website showed that Qilu Pharmaceutical’s application for olaparib’s generic drug listing in four categories was accepted by the NMPA
.
This is the first generic drug application for the product and the first domestic PARP inhibitor for the treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer in adult patients with platinum-containing chemotherapy Maintenance treatment after complete remission or partial remission; first-line maintenance treatment for BRCA-mutated advanced ovarian cancer; maintenance treatment for advanced epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer with BRCA mutation; single-drug treatment for carrying embryos Adult patients with metastatic castration-resistant prostate cancer who have a lineage or somatic BRCA mutation and have failed previous treatments
.
(CDE) Baotai Pharmaceutical and Palm Palm Domperidone tablets have passed the generic drug consistency evaluation Recently, Baotai Pharmaceutical and Palm Palm domperidone tablets have passed the generic drug consistency evaluation
.
Domperidone tablets are gastrointestinal prokinetic drugs, which directly act on the gastrointestinal wall, increase gastrointestinal motility and tension, promote gastric emptying, increase gastric antrum and duodenal movement, coordinate the contraction of the pylorus, and can also enhance The peristalsis of the esophagus and the tension of the lower esophageal sphincter are widely used to treat nausea and vomiting
.
(Minenet) Merck will share anti-coronavirus oral drugs with 105 developing countries on the 27th, the US "Capitol Hill" reported that Merck announced that it will share its antiviral drug "monupivir" for the treatment of COVID-19 with developing countries , To expand the scope of use of this promising treatment
.
According to reports, Merck and its partner Ridgeback Biotherapeutics stated that they have entered into a treatment licensing agreement with the United Nations, allowing 105 low- and middle-income countries to share the drug
.
("Capitol Hill") Eli Lilly/Pfizer terminates global development of osteoarthritis drug tanezumab Recently, Eli Lilly disclosed an important news in its third quarter earnings report
.
In October of this year, the company and its partner Pfizer terminated the global clinical development project of the antibody drug tanezumab, which is a nerve growth factor inhibitor developed for the treatment of osteoarthritis pain
.
According to the information disclosed by Eli Lilly, the two parties made the above decision because tanezumab has suffered serious setbacks in US and European supervision.

.
In the United States, the FDA has issued a complete response letter to the application for the approval of tanezumab's biological products for the treatment of osteoarthritis; in the European Union, the European Medicines Agency's Committee on Pharmaceutical Products for Human Use has issued a negative opinion on the application for the marketing authorization of tanezumab for the treatment of OA
.
(Sina Pharmaceutical News) Novartis terminates the development of gene therapy AVXS-201 The latest news shows that Novartis has decided to abandon the research and development plan of gene therapy AVXS-201, and revealed that "the entire content of the preclinical data does not support the further development of gene therapy AVXS-201 Human clinical trials"
.
(Sina Pharmaceutical News) WHO announced the launch of a vaccine solidarity test to evaluate the next generation of new crown vaccines.
On the 26th, WHO announced the official launch of a new crown vaccine solidarity test
.
This is an international randomized clinical trial program that aims to select the next-generation new crown vaccine candidates with the most development potential and evaluate their safety and effectiveness.
The goal is to provide better protection against virus variants, and for longer protection and so on
.
(WHO) GSK stopped developing anti-GM-CSF monoclonal antibody otilimab to treat COVID-19 According to FierceBiotech, GSK has decided to terminate the clinical development of the antibody drug otilimab for COVID-19
.
There are two reasons.
One is the failure of otilimab in phase 2 clinical trials, and the other is the company's progress in anti-SARS-CoV-2 antibodies
.
At present, the clinical project of otilimab to treat rheumatoid arthritis is still continuing
.
(Sina Medical News) The world's first breast cancer vaccine clinical trial opens.
Recently, researchers at the Cleveland Clinic in the United States will launch a phase I vaccine trial.
The vaccine may also become the first ever vaccine to prevent triple-negative breast cancer
.
The study will evaluate the maximum dose of the vaccine that patients diagnosed with early-stage triple-negative breast cancer can tolerate, and analyze how the vaccine will optimize the body’s immune response.
The trial is expected to be completed in September 2022
.
(Sina Pharmaceutical News) Cinda and Xinhe Biosciences cooperate to develop Sintilimab + mRNA vaccine clinical treatment of tumor No.
28, Xinda Bio and Xinhe Biosciences jointly announced that the two parties have reached a strategic cooperation for the injection of Sintilimab Clinical research has been carried out on the combined treatment of tumor liquid and personalized neoantigen vaccine NEO_PLIN2101
.
According to the cooperation agreement, Innovent will establish a clinical research partnership with Xinhe Biotechnology to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the combination of Sintilimab and NEO_PLIN2101 in cancer subjects , To jointly promote the development of combined immunotherapy for solid tumors, and plan to submit a clinical research application to NMPA in the near future
.
(Medical Rubik's Cube)